Protalex Reports Clinical Progress of PRTX-100 in Rheumatoid Arthritis and Idiopathic Thrombocytopenic Purpura

Protalex, Inc. (OTCBB: PRTX) announced that it continues to make significant progress in its clinical development of PRTX-100 in multiple indications. In rheumatoid arthritis (RA), building on the results of the successful Phase Ia safety study, the company initiated a Phase Ib study in healthy volunteers on June 20, 2007. This study follows the May 4, 2007 filing of an amendment to the company's open Investigational New Drug application with the United States Food and Drug Administration. The amendment included the final Phase Ia safety study report, CMC update, and a protocol for the Phase Ib study. This additional study is designed to gain more detailed information on biomarkers,...

Want to see the full article?

• Purchase this article for only $3.00